Nanush Damarlapally, Vijaylaxmi Thimmappa, Hamza Irfan, Muhammad Sikandari, Krupa Madhu, Aayushi Desai, Peddi Pavani, Syeda Zakir, Manvi Gupta, Maha Mushtaq Khosa, Sohny Kotak, Giustino Varrassi, Mahima Khatri, Satesh Kumar
Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PHIs) are a novel group of drugs used to treat renal anemia, but their benefits vary among different trials. Our meta-analysis aims to assess the safety and efficacy of HIF-PHI versus erythropoiesis-stimulating agents (ESA) in managing anemia among patients with chronic kidney disease (CKD), regardless of their dialysis status. PubMed, Embase, and Google Scholar were queried to discover eligible randomized controlled trials (RCTs). To quantify the specific effects of HIF-PHI, we estimated pooled mean differences (MDs) and relative risks (RR) with 95% CIs...
October 2023: Curēus